Hanna Magdi H, Elliott Kate M, Fung Michelle
Pain Relief Research Unit, King's College School of Medicine, King's College Hospital, London SE5 9RS, UK.
Anesthesiology. 2005 Apr;102(4):815-21. doi: 10.1097/00000542-200504000-00018.
Morphine-6-glucuronide (M6G) has promising preclinical characteristics and encouraging pharmacokinetic features for acute nociceptive pain. Early studies have produced a good safety profile when compared to morphine sulfate, although in surrogate pain models studies, a mixed picture emerged. A study to evaluate the efficacy and safety profile in a clinical setting was designed.
The authors conducted a double-blind, randomized, dose-finding study of patients scheduled to undergo major joint replacement. One hundred patients of both sexes were included, with 50 patients in each group. A loading dose of 10 mg of study medication was given intravenously at induction of anesthesia, and two further doses were allowed during surgery if required. Bolus doses via a patient-controlled analgesia system were given subcutaneously at 2 mg/dose and set at a 10-min lockout. Assessments of pain intensity and relief were recorded during the 24-h period.
There were no statistically significant differences between the treatments for 24-h mean pain intensity. However, pain intensity was significantly higher in the M6G group than in the morphine group at 30 min and 1 h. There was no statistical difference in 24-h mean pain relief or retrospective pain scores at any time point during the 24-h period. The severity of sedation was significantly greater in the morphine group than in the M6G group at 30 min, 1 h, 2 h, and 24 h. Respiratory depression was greater in the morphine group than in the M6G group, and more patients in the morphine group withdrew from the study because of respiratory depression.
Overall, M6G has an analgesic effect similar to that of morphine over the first 24 h postoperatively. However, M6G may be slower onset initially than morphine; therefore, a larger initial dose may be required.
吗啡 - 6 - 葡萄糖醛酸(M6G)在急性伤害性疼痛的临床前研究中具有良好特性及令人鼓舞的药代动力学特征。与硫酸吗啡相比,早期研究显示出良好的安全性,尽管在替代疼痛模型研究中出现了复杂的情况。本研究旨在评估其在临床环境中的疗效和安全性。
作者对计划进行大关节置换的患者进行了一项双盲、随机、剂量探索性研究。纳入100名患者,男女各50名,分为两组。麻醉诱导时静脉注射10 mg研究药物的负荷剂量,手术期间如有需要可再给予两剂。通过患者自控镇痛系统以2 mg/剂量皮下给予推注剂量,锁定时间为10分钟。记录24小时内的疼痛强度和缓解情况评估。
治疗组之间24小时平均疼痛强度无统计学显著差异。然而,M6G组在30分钟和1小时时的疼痛强度显著高于吗啡组。24小时内任何时间点的24小时平均疼痛缓解或回顾性疼痛评分均无统计学差异。吗啡组在30分钟、1小时、2小时和24小时时的镇静严重程度显著高于M6G组。吗啡组的呼吸抑制比M6G组更严重,且吗啡组更多患者因呼吸抑制退出研究。
总体而言,M6G在术后头24小时内具有与吗啡相似的镇痛效果。然而,M6G的起效可能最初比吗啡慢;因此,可能需要更大的初始剂量。